Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report) today and set a price ...

LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

Unicycive Therapeutics said the Food and Drug Administration accepted its application seeking approval of its lead drug candidate as a treatment for an electrolyte disorder related to kidney disease.

UNCY Stock Performance and Moving Averages. In recent trading, Unicycive Therapeutics Inc (UNCY) stock price has shown some volatility, fluctuating 6.50% over the last five trades ...

On Friday, Unicycive Therapeutics Inc (UNCY) stock saw a modest uptick, ending the day at $0.59 which represents a slight increase of $0.02 or 3.51% from the prior close of $0.57. The stock opened at ...

(RTTNews) - Biotechnology company Unicycive Therapeutics, Inc. (UNCY) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum ...